A risk-based statistical investigation of the quantification of polymorphic purity of a pharmaceutical candidate by

Samantha J Barry1, Tran N Pham, Phil J Borman

  • 1Product Development, GlaxoSmithKline, Stevenage, United Kingdom. samantha.j.barry@gsk.com

Analytica Chimica Acta
|December 20, 2011
PubMed